Get started
CARA THERAPEUTICSCARA THERAPEUTICSCARA THERAPEUTICS

CARA THERAPEUTICS

No trades
See on Supercharts
Overview
Financials News Discussions Seasonals

69C chart


Full chart

69C upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪18.73 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.482 CHF
Net income (FY)
‪−99.78 M‬ CHF
Revenue (FY)
‪17.65 M‬ CHF
Shares float
‪45.83 M‬
Beta (1Y)
0.24

Employees


Employees (FY)
55
Change (1Y)
−51 −48.11%
Revenue / Employee (1Y)
‪320.98 K‬ CHF
Net income / Employee (1Y)
‪−1.81 M‬ CHF

About Cara Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher A. Posner
Website
caratherapeutics.com
Headquarters
Stamford
Founded
2004
FIGI
BBG00LVDF3M3
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

69C news



Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 69C is 0.258 CHF — it has decreased by −62.06% in the past 24 hours. Watch CARA THERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CARA THERAPEUTICS stocks are traded under the ticker 69C.
69C stock hasn't changed in a week, the last month showed zero change in price, over the last year CARA THERAPEUTICS has showed a −62.50% decrease.
69C reached its all-time high on Dec 29, 2023 with the price of 0.688 CHF, and its all-time low was 0.258 CHF and was reached on Oct 1, 2024. View more price dynamics on 69C chart.
See other stocks reaching their highest and lowest prices.
69C stock is 163.57% volatile and has beta coefficient of 0.24. Track CARA THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is CARA THERAPEUTICS there?
Today CARA THERAPEUTICS has the market capitalization of ‪18.73 M‬, it has increased by 10.52% over the last week.
Yes, you can track CARA THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
CARA THERAPEUTICS is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
69C net income for the last quarter is ‪−10.57 M‬ CHF, while the quarter before that showed ‪−18.00 M‬ CHF of net income which accounts for 41.25% change. Track more CARA THERAPEUTICS financial stats to get the full picture.
No, 69C doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 55.00 employees. See our rating of the largest employees — is CARA THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CARA THERAPEUTICS EBITDA is ‪−69.58 M‬ CHF, and current EBITDA margin is −578.20%. See more stats in CARA THERAPEUTICS financial statements.
Like other stocks, 69C shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CARA THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.